Large-Scale Body Composition Study Reveals Link between Specific Fat Distributions and Metabolic Diseases
Specific patterns of fat distribution are linked to the presence of Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D), according to a new study published in Obesity. 1 AMRA, the international leader in body composition analysis, today announced the results of a body composition study of over 6,000 subjects, stressing the need to measure and investigate several fat compartments in order to understand and develop treatments for multiple metabolic diseases. The new findings go far beyond what can be described by sex, age, lifestyle, BMI, or a single fat compartment, and have the potential to strongly impact how metabolic conditions will be prevented and managed in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005616/en/
The Obesity study was co-authored in collaboration between AMRA, Pfizer, Westminster University, Linköping University, and UK Biobank. The 6,000 subjects analyzed are part of the UK Biobank Imaging Study, a major national and international health resource. In 2015, UK Biobank announced that AMRA would perform the automated analysis of MRI images for precise fat and muscle measurements. AMRA has now developed the technique of body composition profiling, which allows for precise analysis of multiple variables to describe the complex associations and interactions between fat distribution, muscle volumes, and metabolic status.
Regardless of normal, overweight, or obese BMI class, AMRA’s body composition profiling of the subjects revealed a number of skewed fat distribution patterns, or phenotypes, that cannot be described when looking at a single fat or muscle measurement. These phenotypes are associated with different metabolic disease profiles: some exhibit no metabolic disease, while others exhibit CHD, T2D, or the co-morbidity of the two. Specifically, higher visceral fat and muscle fat was associated with CHD and T2D (p<0.001) while higher liver fat was associated with T2D (p<0.001) and lower liver fat with CHD (p<0.05). Lower visceral fat and muscle fat was also associated with metabolic health (p<0.001), whereas liver fat was non-significant. Associations remained significant when adjusting for sex, age, BMI, alcohol, smoking, and physical activity.
Dr Olof Dahlqvist Leinhard, senior author of the study, commented, “It has been known for some time that there are fat distributions that are disadvantageous from a health perspective. Today, new techniques provide high accuracy and precision, enabling in-depth analyses of the clinical importance of body composition at a large scale. What’s exciting is that, by using a multivariable approach and an intuitive visualization of body composition, we’ve been able to identify a wide range of body composition profiles that could provide the link to increased risk of metabolic diseases.”
Tommy Johansson, Chief Executive Officer of AMRA, added, “These ground-breaking results allow a glimpse into the future where precision diagnostics will provide the backbone to personalized medicine. By better understanding of muscle and fat volumes, and where fat is located in the body, we hope to help redefine disease risk and suitability for treatment. Our vision is that, in the future, our research and technology will be used to assist in the improved prevention, diagnosis, and treatment of a wide range of diseases.”
Today a quarter of the world’s adults have Metabolic Syndrome – a cluster of factors that increase the risk of several chronic diseases, such as heart disease, cancer, stroke, liver disease and diabetes.2 Obesity, CVD and T2D are growing pandemics and leading causes of early death globally, presenting some of the greatest challenges to patients and healthcare systems worldwide.3,4,5,6
The first 6,021 participants from the UK Biobank imaging sub-study – mean age 62.3±7.5 years, and BMI 26.7±4.4 kg/m2 – were scanned using a 6-minutes MRI protocol providing a water and fat separated volumetric dataset covering neck to knees, and a single slice for proton density fat fraction (PDFF) assessment in the liver. For body composition, acquired image data were analyzed for visceral adipose tissue, abdominal subcutaneous adipose tissue, thigh muscle volume, muscle fat infiltration in the anterior thighs, and liver PDFF. Briefly, the image analysis comprised of (1) image calibration, (2) fusion of image stacks, (3) image segmentation, (4) quantification of fat and muscle volumes7,8,9,10,11 and manual quality control by an analysis engineer.
Diagnosis information was gathered through in-patient electronic healthcare records and via touchscreen questionnaires followed by interviews performed by trained nurses. For CHD and T2D, two matched control groups were stratified matched on (1) sex and age, and (2) sex, age, and BMI. Participants were considered metabolic disease free if they did not report any conditions considered to be serious enough to represent metabolically-focused health concerns (e.g. cardiovascular and metabolic diseases, severe chronic conditions, neurological diseases, and cancers).12
The study was carried out as a collaboration between AMRA medical, Pfizer, Westminster University and Linköping University. Funding support was provided by Pfizer.
AMRA is the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amramedical.com.
About UK Biobank
UK Biobank is a major national and international health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40–69 years in 2006–2010 from across the country, when they provided lots of information about their health and well-being and donated samples of blood and urine for long-term storage and analysis, including genetic information. The project has permission to follow participants’ health through medical records. UK Biobank has also embarked on a major project to MRI scan the vital internal organs and body composition of 100,000 participants. Over many years, these detailed data will build a powerful resource to help scientists discover why some people develop particular diseases and others do not, and to suggest new ways of preventing and treating them.
2 Worldwide Definition of the Metabolic Syndrome, International Diabetes Federation (IDF)
3 Chang S-H, et al. JAMA Surg 2014;149:275–87
4 IDF diabetes atlas. 2015. Available at: http://www.diabetesatlas.org [last accessed 06.10.16]
5 Branca F, et al. The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. 2007
6 Klein S, et al. Obesity (Silver Spring) 2011;19:581–7
7 West J, Dahlqvist Leinhard O, Romu T, et al. Feasibility of MR-based Body Composition Analysis in Large Scale Population Studies. PLoS ONE 2016;11(9)
8 Borga M, Thomas EL, Romu T, et al. Validation of a Fast Method for Quantification of Intra-abdominal and Subcutaneous Adipose Tissue for Large Scale Human Studies. NMR Biomed 2015;28(12):1747–53
9 OD Leinhard, A Johansson, J Rydell, et al. Quantitative Abdominal Fat Estimation Using MRI Pattern Recognition. In: Proceedings of the 19th International Conference on Pattern Recognition (ICPR) 08–11 Dec, 2008; Tampa, FL
10 Karlsson A, Rosander J, Romu T, et al. Automatic and Quantitative Assessment of Regional Muscle Volume by Multi-Atlas Segmentation Using Whole-Body Water-Fat MRI. JMRI 2015;41(6):1558–69
11 West J, Romu T, Thorell S, et al.. Precision of MRI-based body composition measurements of postmenopausal women. PLoS One 2018;13(2):e0192495
12 UK Biobank Data Showcase. Available at: http://biobank.ctsu.ox.ac.uk/crystal/ [last accessed 16.11.17]
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Moody’s Completes Acquisition of Omega Performance21.8.2018 00:06 | Tiedote
Moody’s Corporation (NYSE:MCO) announced today that it has completed its acquisition of Omega Performance, a leading provider of online credit training. Moody’s announced its intention to acquire Omega Performance, a business unit of TwentyEighty Inc, on July 8, 2018. Omega Performance offers a wide range of online credit training courses to clients worldwide and serves more than 300 customers, ranging from large global banks to local lending institutions. The acquisition will enhance Moody’s Analytics as a worldwide market standard in credit proficiency for financial institutions that offer consumer, small business and corporate lending. The acquisition of Omega Performance is not expected to have a material impact on Moody’s 2018 financial results. For further information about Moody’s Analytics eLearning solutions, visit www.moodysanalytics.com/elearning-courses. ABOUT MOODY'S CORPORATION Moody's is an essential component of the global capital markets, providing credit ratings, rese
Pacific Drilling Announces Settlement in Mediation Between Quantum Pacific and Ad Hoc Group of Creditors20.8.2018 17:02 | Tiedote
Pacific Drilling S.A. (OTC:PACDQ) (“Pacific Drilling” or the “Company”) today announced that its plan of reorganization filed on July 31, 2018 (the “Plan”), based on a proposal presented to the Company’s Board of Directors by an ad hoc group of its secured creditors (collectively, the “Ad Hoc Group”), now has the full support of the Company’s majority shareholder, Quantum Pacific (Gibraltar) Limited (“QP”). The Plan was already supported by all of the Company’s major creditor interests. With QP’s participation, the Company expects a smooth plan confirmation process and a quick emergence from its Chapter 11 proceedings. Pacific Drilling CEO Paul Reese commented, “The agreement reached by QP and the Ad Hoc Group delivers the final piece needed to make the Company’s Plan a consensual one that has the support of the Company’s major stakeholders. The agreement should allow the Plan to move forward efficiently and expeditiously through the implementation and confirmation process.” Pursuant t
Bella Hadid Headlines True Religion’s Latest Campaign20.8.2018 15:32 | Tiedote
True Religion has tapped Bella Hadid to be the face of the brand. The supermodel embodies all things True Religion, past, present and future; iconic, edgy and everlasting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005283/en/ Bella Hadid Headlines True Religion’s Latest Campaign (Photo: Business Wire) An inherit fan of the brand, Bella was the natural choice to meld the iconic essence of the brand with the modern view of its future. An all-star team was assembled including photographer Boo George, stylist Mimi Cuttrell, and hair and makeup duo Jen Atkin and Mary Phillips to create imagery and complementary looks that usher True Religion into a new era that honors the heritage of the brand. A quintessential, confident LA girl with roots at home and abroad, Bella’s voice was not only an inspiration, but an integral part in imagining this campaign, envisioning the brand through her eyes for the next generation of True
FRISS Brings Claim Fraud Analysis to a Next Level With Web-IQ´s Innovative Online Network Solution20.8.2018 14:30 | Tiedote
Asking your neighbor or friend to sign as a witness to a claim for car damages at your insurance company will work no more, with the new Claim Fraud Analysis feature of FRISS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005039/en/ Eldert van Wijngaarden (Web-IQ) and Philip van Waning (FRISS) shaking hands. (Photo: Business Wire) FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, recently added a new and innovative feature in their fraud analytics solution: Online Network Analysis from Web-IQ. This feature automatically identifies if the claimants and the insured or other involved persons are related to each other in an on-line environment. This is a proven and strong indicator for fraudulent claims. Especially with car accidents and other types of claims where multiple persons are involved, it adds a whole new approach to the traditional claim analyses. “Research sho
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)20.8.2018 14:30 | Tiedote
Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. “On behalf of the entire Veristat team that has supported Alnylam in the development of this therapy, we are humbled to have contributed towards this first-in-class drug approval for Alnylam, for the patients with hATTR amyloidosis and their families,” said John P. Balser, Ph.D., President and Co-Founder of Veristat. “We are continuing to support Alnylam as they look to expand regulatory approval of this treatment to other regions of the world.” Veristat began working with Alnylam over 11 years ago and helped design the studies and prepare the Investigational New Drug (IND) submission for patisiran. Our collaboration continued throughout the entire patisiran program inclusive of a phase 2 study, a phase 3 pivotal study
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry20.8.2018 14:18 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces the line-up for the IBC Future Zone and IABM Future Trends Theatre. Well established as part of the IBC Exhibition, from 14-18 September, the Future Zone brings together the very latest ideas, innovations and concept technologies from international industry and academia and showcases them in a single specially-curated area sitting alongside exhibition Hall 8. This year, the focus is on showing how new technologies grow from their first inception and progress through to research, development, and validation projects; right through to maturing into the ground-breaking applications and future product standards. Major industry trail-blazers presenting their visions of the future, include Japan’s NHK and BBC R&D from the UK. Both companies will demonstrate a number of technology advances, including: Web-VR applications; object-based media scenarios; pathways to 8K resolution for UHD; and Artifici
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme